Caribou Biosciences, Inc. (CRBU)
Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
1. 65
-0.01
-0.6024%
$
173.57M Market Cap
- P/E Ratio
- Div Yield
1.45M Volume
- Eps
$ 1.66
Previous Close Want to track CRBU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CRBU closed today lower at $1.65, a decrease of -0.6024% from yesterday's close, completing a monthly decrease of -30.0847% or -$0.71. Over the past 12 months, CRBU stock gained 3.7736%.
CRBU is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2026, exceeded the consensus estimates by 0.31%. On average, the company has surpassed earnings expectations by 0.1344%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks | 1 week ago
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seekingalpha | 1 month ago
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seekingalpha | 2 months ago
Caribou Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,180 | $5,122 | $2,017.8 | -$3,104.2 | -60.61% |
 Robert Bruce Robert Jeffrey Bruce is VP/Secretary at Bruce & Co Inc. | 250,000 | $854,500 | $427,500 | -$427,000 | -49.97% |
 Point72 Asset Management LP Point72 Asset Management LP | 187,622 | $318,625.37 | $324,023.19 | $5,397.82 | 1.69% |
| RS Richard Slavik Newbridge Financial Services Group Inc. | 2,000 | $3,180 | $3,470 | $290 | 9.12% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 32,200 | $61,180 | $55,867 | -$5,313 | -8.68% |
Caribou Biosciences, Inc. (CRBU) FAQ
What is the stock price today?
The current price is $1.65.
On which exchange is it traded?
Caribou Biosciences, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is CRBU.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 173.57M.
Has Caribou Biosciences, Inc. ever had a stock split?
No, there has never been a stock split.
Caribou Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rachel E. Haurwitz CEO | NASDAQ (NGS) Exchange | 142038108 CUSIP |
| US Country | 97 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Caribou Biosciences, Inc. is a pioneering clinical-stage biopharmaceutical company based in the United States, with international operations, focused on the advancement of genome-edited allogeneic cell therapies. These innovative therapies are designed to combat hematologic malignancies, offering new hope in the fight against challenging diseases. Founded in 2011 and with its headquarters nestled in Berkeley, California, Caribou Biosciences is at the forefront of leveraging cutting-edge biotechnological methodologies to develop treatments that could potentially transform the therapeutic landscape for patients battling blood cancers.
Products and Services
- CB-010 - An allogeneic anti-CD19 CAR-T cell therapy that is currently undergoing a phase 1 clinical trial. This flagship product candidate represents Caribou Biosciences' commitment to pioneering the development of cell therapies. It is specifically designed to treat relapsed or refractory B cell non-Hodgkin lymphoma, targeting the CD19 antigen, a known marker associated with this type of cancer. CB-010 stands out as a beacon of hope for patients who have exhausted other therapeutic options, offering a novel, potentially life-saving treatment modality.
- CB-011 - This allogeneic anti-BCMA CAR-T cell therapy is another innovative product from Caribou Biosciences' pipeline, currently in a phase 1 clinical trial. Specifically tailored for the treatment of relapsed or refractory multiple myeloma, CB-011 targets the BCMA (B-cell maturation antigen), a key player in the progression of multiple myeloma. By focusing on this specific antigen, CB-011 holds the promise of introducing a revolutionary therapeutic option for patients grappling with this challenging disease.
- CB-012 - Rounding out Caribou Biosciences' groundbreaking portfolio is CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is also in phase 1 clinical trial. Dedicated to the treatment of relapsed or refractory acute myeloid leukemia (AML), CB-012 targets CD371, an antigen associated with AML. This cutting-edge therapy embodies the company’s dedication to expanding its impact across different types of hematologic malignancies, offering potential new treatment avenues for patients with AML.
Contact Information
Address: 2929 7th Street
Phone: 510 982 6030
Website: https://cariboubio.com
